288 related articles for article (PubMed ID: 21205080)
1. Inhibiting the PI3K/Akt pathway reversed progestin resistance in endometrial cancer.
Gu C; Zhang Z; Yu Y; Liu Y; Zhao F; Yin L; Feng Y; Chen X
Cancer Sci; 2011 Mar; 102(3):557-64. PubMed ID: 21205080
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Xu Y; Tong J; Ai Z; Wang J; Teng Y
J Obstet Gynaecol Res; 2012 Dec; 38(12):1358-66. PubMed ID: 22612393
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
Zhao S; Chen X; Lu X; Yu Y; Feng Y
Gynecol Oncol; 2007 Apr; 105(1):45-54. PubMed ID: 17240435
[TBL] [Abstract][Full Text] [Related]
4. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
5. Blockage of PI3K/PKB/P27kip1 signaling pathway can antagonize 17 beta-estradiol-induced Ishikawa proliferation and cell cycle progression.
Guo RX; Wei LH; Qiao YH; Wang JL; Tang JM
Chin Med J (Engl); 2006 Feb; 119(3):242-5. PubMed ID: 16537014
[No Abstract] [Full Text] [Related]
6. 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells.
Guo RX; Wei LH; Tu Z; Sun PM; Wang JL; Zhao D; Li XP; Tang JM
J Steroid Biochem Mol Biol; 2006 Apr; 99(1):9-18. PubMed ID: 16567092
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
8. [Influence of long-term treatment with MPA on the biological character of endometrial carcinoma Ishikawa cell].
Zhao SJ; Chen XJ; Feng YJ
Fen Zi Xi Bao Sheng Wu Xue Bao; 2007 Apr; 40(2):103-12. PubMed ID: 17580663
[TBL] [Abstract][Full Text] [Related]
9. Visfatin stimulates endometrial cancer cell proliferation via activation of PI3K/Akt and MAPK/ERK1/2 signalling pathways.
Wang Y; Gao C; Zhang Y; Gao J; Teng F; Tian W; Yang W; Yan Y; Xue F
Gynecol Oncol; 2016 Oct; 143(1):168-178. PubMed ID: 27473926
[TBL] [Abstract][Full Text] [Related]
10. Progestin treatment decreases CD133+ cancer stem cell populations in endometrial cancer.
Guy MS; Qamar L; Behbakht K; Post MD; Sheeder J; Sartorius CA; Spillman MA
Gynecol Oncol; 2016 Mar; 140(3):518-26. PubMed ID: 26731726
[TBL] [Abstract][Full Text] [Related]
11. The G protein-coupled receptor GPR30 mediates the nontranscriptional effect of estrogen on the activation of PI3K/Akt pathway in endometrial cancer cells.
Ge X; Guo R; Qiao Y; Zhang Y; Lei J; Wang X; Li L; Hu D
Int J Gynecol Cancer; 2013 Jan; 23(1):52-9. PubMed ID: 23235274
[TBL] [Abstract][Full Text] [Related]
12. PAK4 confers cisplatin resistance in gastric cancer cells via PI3K/Akt- and MEK/ERK-dependent pathways.
Fu X; Feng J; Zeng D; Ding Y; Yu C; Yang B
Biosci Rep; 2014 Apr; 34(2):. PubMed ID: 27919028
[TBL] [Abstract][Full Text] [Related]
13. [Effects of PD98059 and LY294002 on subcutaneous xenograft of human endometrial carcinoma in nude mice].
Guo RX; Zhang RF; Wang XY; Shi HR; Qiao YH
Zhonghua Fu Chan Ke Za Zhi; 2011 Jun; 46(6):446-52. PubMed ID: 21781587
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of AKT with the orally active allosteric AKT inhibitor, MK-2206, sensitizes endometrial cancer cells to progestin.
Pant A; Lee II; Lu Z; Rueda BR; Schink J; Kim JJ
PLoS One; 2012; 7(7):e41593. PubMed ID: 22911820
[TBL] [Abstract][Full Text] [Related]
16. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
17. Estrogen and progestin regulate metastasis through the PI3K/AKT pathway in human ovarian cancer.
Hua K; Feng W; Cao Q; Zhou X; Lu X; Feng Y
Int J Oncol; 2008 Nov; 33(5):959-67. PubMed ID: 18949358
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Wang Y; Wang Y; Zhang Z; Park JY; Guo D; Liao H; Yi X; Zheng Y; Zhang D; Chambers SK; Zheng W
Oncotarget; 2016 Mar; 7(9):10363-72. PubMed ID: 26824415
[TBL] [Abstract][Full Text] [Related]
19. Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells.
Xie Y; Wang YL; Yu L; Hu Q; Ji L; Zhang Y; Liao QP
J Steroid Biochem Mol Biol; 2011 Sep; 126(3-5):113-20. PubMed ID: 21168492
[TBL] [Abstract][Full Text] [Related]
20. PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer.
Riggio M; Polo ML; Blaustein M; Colman-Lerner A; Lüthy I; Lanari C; Novaro V
Carcinogenesis; 2012 Mar; 33(3):509-18. PubMed ID: 22180571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
